Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin

Appeal Refused In Litigation Involving Reddy’s And First-To-Market Hikma

Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.

Thumbs Up Thumbs Down
As the Supreme Court rejects Amarin, Dr Reddy’s launches a second generic • Source: Alamy

Dr Reddy’s has launched the second generic version of Amarin’s Vascepa (icosapent ethyl) 1g capsules in the US, putting it in direct competition with both the brand and Hikma’s first-to-market generic. The move comes immediately in the wake of the US Supreme Court denying the originator’s petition for certiorari review of a Federal Circuit decision that affirmed as invalid six patents shielding the purified fish oil brand.

The launch shakes up the generic icosapent ethyl market in the US, while also raising questions over supply of the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin